Hippocampal nNOS inhibition induces an antidepressant-like effect: Involvement of 5HT1A receptors

Behavioural Pharmacology

Volumn 25, Issue 3, 2014, Pages 187-196

  Hiroaki Sato, Vinicius A ^a   Sales, Amanda J ^a   Biojone, Caroline ^a   Joca, Sâmia R L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antidepressant; forced swimming stress; nitric oxide; serotonin

Indexed keywords

FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N(G) PROPYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; SEROTONIN 1A RECEPTOR; ANTIDEPRESSANT AGENT; ARGININE; ENZYME INHIBITOR; N(OMEGA)-PROPYLARGININE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INHIBITION; FORCED SWIM TEST; HIPPOCAMPUS; MALE; MICROINJECTION; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD TEST; RAT; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ENZYMOLOGY; EXPLORATORY BEHAVIOR; MENTAL STRESS; METABOLISM; PSYCHOLOGY; SWIMMING; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; FLUOXETINE; HIPPOCAMPUS; MALE; NITRIC OXIDE SYNTHASE TYPE I; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84899922730     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000035     Document Type: Article

References (70)

1. Boucher AA, Arnold JC, Hunt GE, Spiro A, Spencer J, Brown C, et al. (2011).Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 189:170-177.
2. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000).Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118.
4. Carr GV, Lucki I (2011). The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 213:265-287.
5. Cryan JF, Page ME, Lucki I (2002). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J. Pharmacol 436:197-205.
6. De Oliveira RW, Del Bel EA, Guimaraes FS (2000). Behavioral and c-fos expression changes induced by nitric oxide donors microinjected into the dorsal periaqueductal gray. Brain Res Bull 51:457-464.
7. Dhir A, Kulkarni SK (2007a). Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 31:921-925.
8. Dhir A, Kulkarni SK (2007b). Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 568:177-185.
9. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L, Baux G (1999). Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 93:597-603.
10. Garcia-Lecumberri C, Ambrosio E (2000). Differential effect of low doses of intracerebroventricular corticotropin-releasing factor in forced swimming test. Pharmacol Biochem Behav 67:519-525.
11. Garthwaite J, Charles SL, Chess-Williams R (1988). Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:385-388.
12. Gigliucci V, Buckley KN, Nunan J, O'Shea K, Harkin A (2010). A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test. Pharmacol Biochem Behav 94:524-533.
13. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54:129-141.
14. Guimaraes FS, Del Bel EA, Padovan CM, Netto SM, de Almeida RT (1993). Hippocampal 5-HT receptors and consolidation of stressful memories. Behav Brain Res 58:133-139.
15. Harkin A, Connor TJ, Burns MP, Kelly JP (2004). Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 14:274-281.
16. Harkin AJ, Bruce KH, Craft B, Paul IA (1999). Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 372:207-213.
17. Harkin A, Connor TJ, Walsh M St, John N, Kelly JP (2003). Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44:616-623.
18. Harvey BH, Bothma T, Nel A, Wegener G, Stein DJ (2005). Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K-beta in an animal model of repeated trauma. Hum Psychopharmacol 20:367-373.
19. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ (2004). Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology 29:952-959.
20. Heiberg IL, Wegener G, Rosenberg R (2002). Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134:479-484.
21. Inan SY, Yalcin I, Aksu F (2004). Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 77:457-464.
22. Iuras A, Telles MM, Bertoncini CR, Ko GM, de Andrade IS, Silveira VL, Ribeiro EB (2005). Central administration of a nitric oxide precursor abolishes both the hypothalamic serotonin release and the hypophagia induced by interleukin-beta in obese Zucker rats. Regul Pept 124:145-150.
23. Jefferys D, Funder J (1996). Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur J Pharmacol 295:131-135.
24. Joca SR, Guimaraes FS (2006). Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 185:298-305.
25. Joca SR, Padovan CM, Guimaraes FS (2003a). Activation of post-synaptic 5-T(1A) receptors in the dorsal hippocampus prevents learned helplessness development. Brain Res 978:177-184.
26. Joca SR, Padovan CM, Guimaraes FS (2003b). Stress, depression and the zippocampus. Rev Bras Psiquiatr 25 (Suppl 2):46-51.
27. Joca SR, Zanelati T, Guimaraes FS (2006). Post-stress facilitation of serotonergic, but not noradrenergic, neurotransmission in the dorsal hippocampus prevents learned helplessness development in rats. Brain Res 1087:67-74.
28. Joca SR, Ferreira FR, Guimaraes FS (2007). Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 10:227-249.
29. Keser A, Balkan B, Gozen O, Kanit L, Pogun S (2011). Hippocampal neuronal nitric oxide synthase (nNOS) is regulated by nicotine and stress in female but not in male rats. Brain Res 1368:134-142.
30. Knowles RG, Moncada S (1994). Nitric oxide synthases in mammals. Biochem J 298:249-258.
31. Kuhn DM, Arthur RE Jr. (1996). Inactivation of brain tryptophan hydroxylase by nitric oxide. J Neurochem 67:1072-1077.
32. Kuhn DM, Arthur R Jr. (1997). Molecular mechanism of the inactivation of tryptophan hydroxylase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. J Neurosci 17:7245-7251.
33. Kumar A, Garg R, Gaur V, Kumar P (2010). Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Res 1311:73-80.
34. Linden DR, El-Fakahany EE (2002). Microglial derived nitric oxide decreases serotonin content in rat basophilic leukemia (RBL-2H3) cells. Eur J. Pharmacol 436:53-56.
35. Lopez JF, Chalmers DT, Little KY, Watson SJ (1998). A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 43:547-573.
36. Lundberg J, Borg J, Halldin C, Farde L (2007). A PET study on regionalzoexpression of 5-HT1A receptors and 5-HTT in the human brain. Psychopharmacology (Berl) 195:425-433.
37. Mutlu O, Ulak G, Laugeray A, Belzung C (2009). Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol Biochem Behav 92:82-87.
38. Ogren SO, Ross SB, Hall H, Holm AC, Renyi AL (1981). The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor. Acta Psychiatr Scand Suppl 290:127-151.
39. Oliveira RM, Guimaraes FS, Deakin JF. (2008). Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 41:333-341.
40. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322.
41. Padovan CM, Guimaraes FS (1993). Attenuation of behavioral consequences of immobilization stress by intra-hippocampal microinjection of zimelidine. Braz J Med Biol Res 26:1085-1089.
42. Palmer RM, Ashton DS, Moncada S (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.
43. Paxinos G,Watson C (1997). The Rat Brain In Stereotaxic Coordinates. 2nd ed. San Diego, USA: Academic Press, Inc.
44. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
45. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
46. Segieth J, Pearce B, Fowler L,Whitton PS (2001). Regulatory role of nitric oxide over hippocampal 5-HT release in vivo. Naunyn Schmiedebergs Arch Pharmacol 363:302-306.
47. Seidenbecher T, Laxmi TR, Stork O, Pape HC (2003). Amygdalar and hippocampal theta rhythm synchronization during fear memory retrieval. Science 301:846-850.
48. Sevgi S, Ozek M, Eroglu L (2006). L-NAME prevents anxiety-like and depressionlike behavior in rats exposed to restraint stress. Methods Find Exp Clin Pharmacol 28:95-99.
49. Sheline YI (1996). Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol Psychiatry 1:298-299.
50. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999). Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19:5034-5043.
51. Shumake J, Edwards E, Gonzalez-Lima F (2002). Dissociation of septohippocampal metabolism in the congenitally helpless rat. Neuroscience 114: 373-377.
52. Slattery DA, Cryan JF (2012). Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 7:1009-1014.
53. Smith JC, Whitton PS (2000). Nitric oxide modulates N-methyl-D- aspartateevoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat. Neurosci Lett 291:5-8.
54. Snyder SH, Ferris CD (2000). Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 157:1738-1751.
55. Steinert JR, Chernova T, Forsythe ID (2010). Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 16:435-452.
56. Ulak G, Mutlu O, Tanyeri P, Komsuoglu FI, Akar FY, Erden BF (2010). Involvement of serotonin receptor subtypes in the antidepressant-like effect of TRIM in the rat forced swimming test. Pharmacol Biochem Behav 95:308-314.
57. Van Riel E, Meijer OC, Steenbergen PJ, Joels M (2003). Chronic unpredictable stress causes attenuation of serotonin responses in cornu ammonis 1 pyramidal neurons. Neuroscience 120:649-658.
58. Van Riel E, van Gemert NG, Meijer OC, Joels M (2004). Effect of early life stress on serotonin responses in the hippocampus of young adult rats. Synapse 53:11-19.
59. Verge D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, Hamon M (1986). Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 6:3474-3482.
60. Volke V, Wegener G, Bourin M, Vasar E (2003). Antidepressant-and anxiolyticlike effects of selective neuronal NOS inhibitor 1-(2- trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 140:141-147.
61. Wang D, An SC, Zhang X (2008). Prevention of chronic stress-induced depressionlike behavior by inducible nitric oxide inhibitor. Neurosci Lett 433:59-64.
62. Wegener G, Volke V, Rosenberg R (2000). Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 130:575-580.
63. Wegener G, Volke V, Harvey BH, Rosenberg R (2003). Local but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 959:128-134.
64. Wegener G, Harvey BH, Bonefeld B, Muller HK, Volke V, Overstreet DH, Elfving B (2010). Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J. Neuropsychopharmacol 13:461-473.
65. Willner P (1984). The validity of animal models of depression. Psychopharmacology (Berl) 83:1-16.
66. Willner P (1990). Animal models of depression: an overview. Pharmacol Ther 45:425-455.
67. Yildiz F, Erden BF, Ulak G, Utkan T, Gacar N (2000). Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 149:41-44.
68. Zhang HQ, Fast W, Marletta MA, Martasek P, Silverman RB (1997). Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-Larginine. J Med Chem 40:3869-3870.
69. Zhou QG, Hu Y, Hua Y, Hu M, Luo CX, Han X, et al. (2007). Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 103:1843-1854.
70. Zhu CB, Hewlett WA, Francis SH, Corbin JD, Blakely RD (2004). Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. Eur J Pharmacol 504:1-6.